Tag : INTENSIVE TARGETING

CONFERENCE UPDATE

The Ez-PAVE trial: Intensive LDL-C targeting reduces 3-year CV events in ASCVD patients
The Ez-PAVE trial showed that intensive LDL-C targeting <55mg/dL significantly reduced 3-year composite cardiovascular events compared with conventional targeting <70mg/dL in patients with ASCVD, without increasing major safety concerns, supporting a more aggressive LDL-C control in line with current guidelines.